Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Type:
Application
Filed:
March 11, 2024
Publication date:
July 25, 2024
Inventors:
Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
Abstract: The present disclosure relates to a heterocyclic compound represented by Chemical Formula 1, an organic light emitting device including the same, and a composition for an organic material layer.
Type:
Application
Filed:
June 14, 2022
Publication date:
July 25, 2024
Applicant:
LT MATERIALS CO., LTD.
Inventors:
Cheol Hun JEONG, Hyun Joo LEE, Young Seok NO, Dong Jun KIM
Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
Type:
Application
Filed:
November 9, 2023
Publication date:
July 25, 2024
Inventors:
Minna BUI, Patrick R. CONLON, Julio H. CUERVO, Daniel A. ERLANSON, Junfa FAN, Bing GUAN, Brian T. HOPKINS, Tracy J. JENKINS, Gnanasambandam KUMARAVEL, Alexey A. LUGOVSKOY, Doug MARCOTTE, Noel POWELL, Daniel SCOTT, Laura SILVIAN, Art TAVERAS, Deping WANG, Min ZHONG
Abstract: A compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R1, R2, R3, ring A, and ring B in formula (1) respectively have the same meanings as defined in the specification.
Abstract: The present invention is directed to a process for the synthesis of (1R, 4R, 5S)-4-(2-chloroethyl)-1-((S)-((S)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.
Type:
Application
Filed:
October 14, 2020
Publication date:
July 25, 2024
Inventors:
Kelvin YONG, John TRAVERSE, Maryll GEHERTY
Abstract: The present invention relates to a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein LG, A, n, m and p are as defined in the Summary of the Invention.
Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
Type:
Application
Filed:
March 11, 2024
Publication date:
July 25, 2024
Inventors:
Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
Abstract: Disclosed are a polymorph of (S)-1-(2-((S)-3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide, a composition comprising the polymorph, a use method therefor and a preparation method therefor.
Type:
Application
Filed:
May 12, 2022
Publication date:
July 25, 2024
Applicant:
Betta Pharmaceuticals Co., Ltd.
Inventors:
Houxian ZU, Liang CHEN, Xizhen SONG, Xintao ZHAO, Kai CHEN, Xiaoyun LIU, Jin WANG, Zhifang XIA, Ying XU, Yuanzheng ZHOU, Lieming DING, Jiabing WANG
Abstract: The present invention provides a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically-acceptable salt thereof or a prodrug thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as an Lp-PLA2 inhibitor, wherein R1, R2, Rx, Ry, Rz, Q, U, X, m, n, and A are defined in the description.
Abstract: The present disclosure relates to an organic compound and an organic light emitting diode and an organic light emitting device each including the same, and more specifically, relates to an emitting compound of following and an organic light emitting diode and an organic light emitting device each including the organometallic compound.
Type:
Application
Filed:
October 3, 2023
Publication date:
July 25, 2024
Inventors:
Seon-Keun YOO, Young-Jun YU, Seong-Su JEON, Sang-Beom KIM, Gi-Baek LEE, Dae-Hyuk CHOI, Dong-Jun KIM, Jun-Tae MO
Abstract: The present disclosure relates to an organic compound and an organic light emitting diode and an organic light emitting device each including the same, and more specifically, relates to an emitting compound of following and an organic light emitting diode and an organic light emitting device each including the organometallic compound.
Type:
Application
Filed:
October 16, 2023
Publication date:
July 25, 2024
Inventors:
Seon-Keun YOO, Young-Jun Yu, Seong-Su Jeon, Sang-Beom Kim, Gi-Baek Lee, Dae-Hyuk Choi, Dong-Jun Kim, Jun-Tae Mo
Abstract: A structural analog of Cyclotheonellazole A, and a synthetic method therefor and an application method thereof are provided. A compound with a structure of formula (I) and a pharmaceutically acceptable salt thereof are provided. The formula (I) is as follows: R1, R2, R3 and R4 are independently selected form the group consisting of H, a C1-C6 alkyl group, a C1-C6 alkoxy group, a halogen group, a hydroxyl group, an amino group, a nitro group, a cyano group, and a sulfydryl group. Based on the total synthetic route of Cyclotheonellazole A, the classical reverse synthesis analysis is utilized, the structural modification is purposefully carried out, a mother nucleus of the natural product remains unchanged, and the structural analog 1a is obtained by replacing a left side chain with a simple formylamine, thereby confirming the excellent protease inhibitory activity thereof, and having a strong application prospect in the pharmaceutical industry.
Abstract: Provided are boron-containing compounds. Also provided are formulations comprising these boron-containing compounds. Further provided are OLEDs and related consumer products that utilize these boron-containing compounds.
Type:
Application
Filed:
January 11, 2024
Publication date:
July 25, 2024
Applicant:
Universal Display Corporation
Inventors:
Peter WOLOHAN, Tyler FLEETHAM, Jerald FELDMAN
Abstract: Provided herein are KRAS G12D proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS G12D PROTACs, and methods of making and using the KRAS G12D PROTACs, e.g., to promote degradation of KRAS G12D and/or treat KRAS G12D-associated cancers. In an embodiment, the KRAS G12D PROTAC has the following structural formula: [KRAS G12Di]-L?-[Degron], or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., KRAS G12Di, L?, Degron) are as described herein.
Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
Type:
Application
Filed:
December 15, 2023
Publication date:
July 25, 2024
Inventors:
Bernard BARLAAM, Michael BODNARCHUK, Avipsa GHOSH, Frederick GOLDBERG, Sudhir HANDE, Phillip LICHTOR, Kun SONG, Qibin SU, Reem TELMESANI, James SHEPPECK
Abstract: Provided herein are methods of making metal-organic frameworks comprising forming a suspension capable of producing metal-organic frameworks; inducing flocculation of the suspension to form a plurality of flocs; allowing the flocs to separate from the suspension and produce a solid phase comprising metal-organic frameworks and a supernatant liquid phase; separating the solid phase from the supernatant liquid phase; and recovering the metal-organic frameworks from the solid phase. The present methods include dissolving a metal salt and at least one ligand in a solvent to form the suspension.
Type:
Application
Filed:
May 20, 2022
Publication date:
July 25, 2024
Inventors:
Wesley Sattler, Nicole M. Herb, Matthew T. Kapelewski, Aaron W. Peters
Abstract: Yttrium complexes and related methods are provided. A method for preparing a yttrium complex comprises contacting a metal alkylcyclopentadienyl compound and a yttrium trihalide compound in a non-coordinating solvent, so as to obtain a tris(alkylcyclopentadienyl)yttrium complex. A composition comprises a tris(alkylcyclopentadienyl)yttrium complex.
Type:
Application
Filed:
January 12, 2024
Publication date:
July 25, 2024
Inventors:
Vagulejan Balasanthiran, Scott A. Laneman
Abstract: The present invention relates to new cerium (IV) complexes. Further, the present invention relates to electronically doped semiconductor materials and an electronic component comprising cerium (IV) complexes. A further object of the invention is the use of the cerium (IV) complexes as electron acceptors, especially as p-dopants and electron transport materials in organic electronic components.
Type:
Application
Filed:
March 8, 2022
Publication date:
July 25, 2024
Inventors:
Sascha Dorok, Marcus Papmeyer, Leonard Eymann
Abstract: The invention relates to an organic molecule, in particular for the use in optoelectronic devices. According to the invention, the organic molecule has a structure of Formula I: Formula I, wherein X is selected from N and CRa, and Rd and Re are each independently selected from the group consisting of: hydrogen, deuterium, N(Ra)2, ORa, Si(Ra)3, B(ORa)2, B(Ra)2, OSO2Ra, CF3, CN, F, Cl, Br, I, C1-C40-alkyl, C1-C40-alkoxy, C1-C40-thioalkoxy, C2-C40-alkenyl, C2-C40-alkynyl, C2-C57-aryl, and C2-C57-heteroaryl.
Abstract: A heterocyclic compound, an organic light-emitting device including the heterocyclic compound, and an electronic apparatus including the organic light-emitting device. Utlization of the heterocyclic compound in the organic light-emitting device may enhance or improve the operating characteristics of the device, such as driving voltage, luminance, luminescence efficiency, and/or lifespan.
Abstract: Nuclear targeting tags having a phenylboronate targeting moiety, a linker, a chemically linkable end group suitable for linking the targeting moiety to a molecule of interest, and optionally a spacer between the linker and chemically linkable end group. Also provided are compounds including the nuclear targeting tag covalently bonded to a molecule of interest, such as a drug, probe, dye, peptide, protein, drug candidate, or natural product. Also provided are methods of introducing a molecule of interest into a nucleus of a cell using the nuclear targeting tag. Also provided are methods for preparing the nuclear targeting tags.
Type:
Application
Filed:
May 4, 2022
Publication date:
July 25, 2024
Inventors:
David Klick, Kaelyn Wilke, Ashwini Ghogare, Ravindra Vikram Singh
Abstract: Provided are an organic electroluminescent material and a device comprising the same. The organic electroluminescent material is a compound having a structure of Formula 1, and the compound can be used as an electron blocking material, a hole transporting material or a host material in an organic electroluminescent device. The compound enables the organic electroluminescent device to maintain a low voltage level or further reduce the voltage, have higher device efficiency and/or a longer device lifetime, and provide better overall performance of the device. Further provided are an organic electroluminescent device comprising the compound and a compound composition comprising the compound.
Abstract: The present invention relates to a specific triazine silane compound, an oligomer thereof, a mixture comprising said compound and/or said oligomer, as well as a respective storage and working solution. Furthermore, the present invention relates to a synthesis method for said specific triazine silane compound, and the use of said working solution as a surface treatment solution.
Type:
Application
Filed:
March 11, 2022
Publication date:
July 25, 2024
Applicant:
Atotech Deutschland GmbH & Co. KG
Inventors:
Valentina BELOVA-MAGRI, Stefanie ACKERMANN, Philipp HAARMANN, Martin THOMS, Norbert LĆTZOW, Jan KNAUP, Tatjana KĆNIGSMANN, Bernd FROESE
Abstract: Precursors and related methods are provided. A precursor comprises a cyclosilazane compound. The cyclosilazane compound is a reaction product of an aminosilane and a halosilane. A method for forming the precursor comprises obtaining an aminosilane, obtaining a halosilane, and contacting the aminosilane and the halosilane to obtain the precursor. A method for forming a silicon-containing film using the precursor is also provided, among other embodiments.
Type:
Application
Filed:
January 15, 2024
Publication date:
July 25, 2024
Inventors:
DaHye Kim, YeRim Yeon, SangJin Lee, MinSeok Ryu, SeongCheol Kim
Abstract: The present invention relates to complexes comprising a prostate-specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.
Abstract: Provided herein is a process for producing alkyl phosphate and a salt thereof of Formula I, wherein, R=C16-22 and M=H, K or Na the said process comprising steps of: A) reacting fatty alcohol of Formula II with polyphosphoric acid (PPA) of 115-120% of Formula III; B) converting the product of step A) into granules; C) ageing the granules of alkyl phosphate esters for maximum 10 days; D) wetting the granules with water after ageing; and E) filtering the granules; F) optionally neutralizing the filtered granules with an aqueous solution of alkali metal hydroxides; and G) drying the granules under reduced pressure. The product obtained contains at least 90:10 ratio of mono:dialkyl phosphate ester, free phosphoric acid<0.7 wt. % and free fatty alcohol<1.5 wt. % and upon neutralization the composition contains at least 89:11 ratio of monoalkyl:dialkyl phosphate salt, inorganic phosphate<0.9 wt. %, and free fatty alcohol<1.5 wt. %.
Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.
Type:
Application
Filed:
April 5, 2024
Publication date:
July 25, 2024
Inventors:
Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
Abstract: Provided herein are inhibitors of TNF?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF? inhibitory compounds for the treatment of diseases or disorders.
Abstract: The present invention covers phosphorus derivatives of general formula (I), in which R1, R2, R3, R4, R5, R6, X1, X2, X3, X4 and Y are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, especially diseases associated with SOS1, as a sole agent or in combination with other active ingredients.
Type:
Application
Filed:
April 13, 2022
Publication date:
July 25, 2024
Inventors:
Felix PAPE, Steffen GRESSIES, Timo STELLFELD, Jeremie Xavier G MORTIER, Atanas Marinov KAMBUROV, Benjamin BADER, Keith GRAHAM, Roman HILLIG, Jens SCHRODER, Christoph Philipp HETHEY, Matthias ARLT, Gerhard SIEMEISTER, Katrin NOWAK-REPPEL, Michael ERKELENZ
Abstract: Disclosed herein are cyclic thiol prodrugs, and pharmaceutical compositions thereof. The prodrugs and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example, cystinuria, cystinosis, cancer, neurodegenerative disease, Parkinson's disease, Huntington's disease, malaria, nonalcoholic fatty liver disease, radiation poisoning, arsenic poisoning, radioprotection, Wilson's disease or rheumatoid arthritis.
Type:
Application
Filed:
February 6, 2024
Publication date:
July 25, 2024
Inventors:
Manoj Chandrasinhji Desai, Siva R. Kamma
Abstract: A compound comprising a first ligand LA of Formula I, In Formula I, moieties A, B, C, and D are each independently a monocyclic ring or a polycyclic fused ring system; each of Z1, Z2, and X1 to X7 is independently C or N; K is selected from a direct bond and a linker; each R?, R?, RA, RB, RC, and RD is hydrogen or a General Substituent defined herein; any two substituents may be joined or fused to form a ring; LA is joined to a metal M that has an atomic mass of at least 40; M may be coordinated to other ligands; and LA may be joined with other ligands. Formulations, OLEDs, and consumer products containing the compound are also provided.
Type:
Application
Filed:
November 27, 2023
Publication date:
July 25, 2024
Applicant:
Universal Display Corporation
Inventors:
Zhiqiang JI, Pierre-Luc T. BOUDREAULT, Derek Ian WOZNIAK, Tongxiang (Aaron) LU, Alexey Borisovich DYATKIN
Abstract: The present invention relates to a heterocyclic modified platinum complex containing an ONCN tetradentate ligand, which has a structure as shown in Chemical Formula (I). The complex is used in organic light-emitting diodes, has a relatively low driving voltage and relatively high luminous efficiency, can significantly prolong the service life of a device, and has the potential for application in the field of organic electroluminescent devices. The present invention further provides an organic electroluminescent device including a cathode, an anode and an organic layer, the organic layer includes one or more layers of a hole injection layer, a hole transport layer, a light-emitting layer, a hole blocking layer, an electron transport layer and an electron injection layer, and at least one layer in the organic layer contains the compound as shown in Structural Formula (I).
Abstract: A method for producing a bipyridine derivative represented by the following formula (3) includes a step of obtaining a metal complex as an intermediate. In the formula (3), R13 to R20 each represent a hydrogen atom or a substituent, the plurality of R13 to R20 may be the same or different, at least one of six Rs consisting of two R14s, two R15s, and two R16s represents a substituent, at least one of two R17s represents a hydrogen atom, any two substituents of R13 to R20 may be bonded to each other to form a ring, each of R17 to R20 may contain a halogen atom or a pyrrolyl group optionally having a substituent, and at least one of R14 to R16 contains a halogen atom or a pyrrolyl group optionally having a substituent.
Type:
Application
Filed:
May 20, 2022
Publication date:
July 25, 2024
Applicant:
SUMITOMO CHEMICAL COMPANY, LIMITED
Inventors:
Kentaro MASE, Norifumi KOBAYASHI, Koji ISHIWATA
Abstract: A metal complex of general formula (I): wherein M is a metal selected from the group consisting of titanium, zirconium, and hafnium; Cyc is a cyclic ligand selected from cyclopentadienyl, indenyl, and fluorenyl and which may contain one or more substituents; Z is an anionic ligand L is a sulfilimine-containing ligand of general formula (II): wherein Sub1 and Sub2 are aromatic residues which, independently from each other, may be unsubstituted or which may contain at least one substituent. Also provided is the use of the compound for polymerization of monomers and a process for producing polymers using the metal complex.
Type:
Application
Filed:
April 8, 2022
Publication date:
July 25, 2024
Applicant:
ARLANXEO NETHERLANDS B.V.
Inventors:
Alexandra BERTHOUD, Victor Fidel QUIROGA-NORAMBUENA, Johannes Hendricus Wilhelmus VAN DE MOOSDIJK
Abstract: The present invention provides crystal forms of the compound Kuding saponin A, and a pharmaceutical composition and a use thereof. The crystal forms comprise crystal forms A, B, C, D, E, G, J, K and L. Characteristic peaks in the X-ray powder diffraction (XRPD) pattern of each crystal form are as described in the application. The crystal forms of the present invention are stable under suitable conditions, especially crystal forms A, C and J. The crystal forms of the present invention can be used to prepare a pharmaceutical composition for treating pulmonary disease.
Abstract: The present invention discloses synthesis of nicotinamide riboside chloride (NRCI). More particularly, the present invention describes cost effective and industrially scalable process for the synthesis of NRCI in amorphous form.
Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine analogs, methods of making, and uses of the same. In particular, polyvalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
Type:
Application
Filed:
November 27, 2023
Publication date:
July 25, 2024
Inventors:
Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao, Ruiming Zou, Aldrich N.K. Lau, David Yu, Guijun Yu, Zhixia Li
Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Nicotinamide N-methyltransferase (NNMT), and formulations composing such compounds. The compounds and formulations may be used as a medicament, for example in the treatment of cancer, metabolic disease, or neurodegenerative disease. The compounds may be of formula (I).
Type:
Application
Filed:
March 30, 2022
Publication date:
July 25, 2024
Applicant:
UNIVERSITEIT LEIDEN
Inventors:
Nathaniel I. Martin, Yonghzi Gao, Matthijs Van Haren, Ned Buijs, Richard Bramwell Parsons, Monica Emanuelli, Davide Sartini
Abstract: Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemically enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.
Type:
Application
Filed:
March 12, 2024
Publication date:
July 25, 2024
Inventors:
Sukumar SAKAMURI, Curt W. BRADSHAW, Laxman ELTEPU, Bryan R. MEADE, Son LAM
Abstract: The present disclosure relates to a crystalline form of (((((E)-1-((8S,9S,10R, 13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethylidene)amino)oxy)methyl dihydrogen phosphate), and pharmaceutically acceptable salts thereof, which may be useful in methods of treatment of the human or animal body. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use in the treatment of disorders, such as managing inflammation (e.g., inflammation resulting from traumatic brain injury or stroke).
Type:
Application
Filed:
April 19, 2022
Publication date:
July 25, 2024
Inventors:
Raymond Brent MILLER, Natalie KELK, David PEARSON, Gideon SHAPIRO
Abstract: Methods of enhancing efficiency of downstream chromatography steps for purification of proteins comprising: (a) passing a composition comprising a polypeptide of interest and various contaminants through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pi of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and at least one contaminant, (b) overloading the ion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; (c) collecting the effluent from the ion exchange membrane comprising the polypeptide of interest; (d) subjecting the membrane effluent comprising the polypeptide of interest to a purification step of similar charge as the previous membrane,
Type:
Application
Filed:
March 1, 2024
Publication date:
July 25, 2024
Applicant:
Genentech, Inc.
Inventors:
Jerome Joseph BILL, JR., Arick Michael BROWN, Christopher John DOWD, Brooke Ellen THAYER
Abstract: Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, tetra-, and/or penta-peptides containing two or more aspartic acid residues. The degradation of several of the vitamin and other constituents vitamin-mineral supplements can be considerably slowed by composition incorporating such peptides, particularly if soluble (and thus bioavailable) forms of copper and/or iron are also present. The peptides can be hydrolyzed by the normal digestive process thus releasing bound metals. Multiple aspartate peptide(s) compositions with foods, topical or oral drugs, cosmetic, and hair care products can replace synthetic chelating preservative agents. Methods are also described to effectively slow degradation and preserve the above products using multiple aspartate peptides.
Abstract: The present application relates to a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions comprising same. The use of such compounds, pharmaceutically acceptable salts thereof or pharmaceutical compositions for inhibiting the activity of an IL-I receptor in a cell, or for treating IL-1 related diseases, disorders or conditions such as inflammatory diseases in a subject, is also described.
Type:
Application
Filed:
August 27, 2021
Publication date:
July 25, 2024
Inventors:
Xin HOU, Azade GERANURIMI, William D. LUBELL, Sylvain CHEMTOB, Christiane QUINIOU, Colin CHENG
Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
Type:
Application
Filed:
November 14, 2023
Publication date:
July 25, 2024
Inventors:
Patrick J. BURKE, Scott JEFFREY, Joseph Z. HAMILTON
Abstract: Disclosed is a method for preventing or treating cancer by using GnRH and telomerase antagonist-derived peptide HS1002, wherein the present polypeptide can be used to effectively treat cancer and is effective in cancer having a high TERT expression or high telomerase activity, especially, prostate cancer.
Type:
Application
Filed:
January 19, 2024
Publication date:
July 25, 2024
Applicant:
Research & Business Foundation Sungkyunkwan University
Inventors:
Hyung Sik KIM, Jae Hyeon PARK, Sang Jeon CHUNG
Abstract: The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.
Type:
Application
Filed:
June 22, 2021
Publication date:
July 25, 2024
Inventors:
William SCHIEF, Jon STEICHEN, Torben SCHIFFNER, Xiaozhen HU, Christoper COTTRELL
Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
Abstract: Provided are stapled antimicrobial peptides (i.e., StAMPs) and methods of using the same (e.g., for treating bacterial infections caused by Gram-negative bacteria). In certain embodiments, the stapled peptides are based on the amino acid sequence of the antimicrobial peptide Esculentin-1A but include certain modifications that have been found to confer advantageous properties (e.g., improved antimicrobial activity, selectivity for killing Gram-negative bacteria, and/or reduced toxicity). Also provided are unstapled peptides which can serve as synthetic precursors to the stapled peptides provided herein.